Infraredx, a medical device manufacturer working in the coronary artery disease sector, has formed an agreement with HealthTrust, a group purchasing organization to make available its novel dual-modality intravascular imaging technology to the group’s member organizations. The TVC Imaging System will be offered to 1,400 acute care facilities.

The technology is used to guide percutaneous coronary interventions (PCI) by incorporating near-infrared spectroscopy (NIRS) to detect lipid-core plaques and intravascular ultrasound (IVUS) to visualize the blood vessel, including the structure of plaques and the degree of stenosis, or narrowing, due to plaque build-up. Lipid-core plaque is a fatty coronary artery plaque known to cause PCI complications, and the rupture of lipid-core plaque is associated with most heart attacks.

“We are pleased to be selected by HealthTrust to provide our innovative TVC Imaging System now to more than 25% of the hospital healthcare facilities across the United States,” said Don Southard, president and chief executive officer of Infraredx. “Our contract will enable HealthTrust members access to our novel dual-modality intravascular imaging technology, which provides valuable information for physicians to make procedural and patient care decisions aimed at improving clinical outcomes and lowering healthcare costs.”

For more information, visit Infraredx.